-

NanoString's GeoMx Mouse Whole Transcriptome Atlas Expands Leadership in Spatial Genomics by Enabling Genome-Wide RNA Profiling

Accelerating Discovery by Providing High Throughput Spatial Analysis of any RNA Target in the Primary Model Organism for Discovery

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the commercial availability of the Mouse Whole Transcriptome Atlas (WTA) for spatial analysis research using the GeoMx® Digital Spatial Profiler (DSP). This launch extends the GeoMx RNA portfolio, which combines the power of spatial biology and Next Generation Sequencing (NGS), to enable full transcriptome spatial RNA and high-plex protein analysis on the GeoMx DSP.

The GeoMx Mouse WTA provides an unbiased, spatial view of all protein-coding genes and is designed for NGS readout on Illumina sequencers. The WTA extends the GeoMx RNA Assay portfolio from a focus on oncology and immunology to new applications in neuroscience, developmental biology, and additional diverse fields. The mouse WTA utilizes the same workflow and chemistry as other GeoMx products to enable robust and sensitive performance in formalin-fixed paraffin-embedded (FFPE) or Fresh Frozen samples.

"The ability to study – with high sensitivity – regions near plaque formations in Alzheimer's disease mouse models is enabling important findings, including our recent identification of a microglial spatial signature, for example," said Dr. Michael Sasner, senior research scientist and MODEL-AD Center manager at The Jackson Laboratory. "These studies in novel mouse models should enable MODEL-AD to understand how the underlying biological mechanisms of AD may vary across brain regions with age, and to map where AD-related changes in expression start and how they spread with disease progression."

"The GeoMx Mouse WTA is a key milestone for NanoString, bringing unbiased RNA profiling for the primary animal model for discovery research, which represents about 30% of the addressable market," said Chad Brown, senior vice president of Sales and Marketing, NanoString. "The strong enthusiasm for the products in our Technology Access Program highlights the appetite for whole transcriptome spatial analysis on GeoMx DSP."

The GeoMx Mouse WTA platform provides the opportunity to examine the relationship between pathology and gene expression within a tissue section. This technology enables measurement of all gene activity in tissue sections, across brain regions and ages, and to map where disease-related changes in expression occur.

To learn more about NanoString's GeoMx Digital Spatial Profiler, please visit https://www.nanostring.com/products/geomx-digital-spatial-profiler/geomx-dsp.

About NanoString Technologies, Inc.

NanoString Technologies is a leading provider of life science tools for discovery and translational research. The company's nCounter® Analysis System is used in life sciences research and has been cited in more than 4,300 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's GeoMx® Digital Spatial Profiler enables highly multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections.

For more information, please visit www.nanostring.com.

NanoString, NanoString Technologies, the NanoString logo, GeoMx, and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.

Contacts

Doug Farrell, NanoString
Vice President, Investor Relations & Corporate Communications
dfarrell@nanostring.com
Phone: 206-602-1768

NanoString Technologies, Inc.

NASDAQ:NSTG

Release Versions

Contacts

Doug Farrell, NanoString
Vice President, Investor Relations & Corporate Communications
dfarrell@nanostring.com
Phone: 206-602-1768

More News From NanoString Technologies, Inc.

NanoString Technologies to Be Acquired by Bruker Corporation

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (“NanoString” or “the Company”), a leading provider of life science tools for discovery and translational research, today announced that substantially all of its assets will be acquired by Bruker Corporation (“Bruker”), a global life science analytical instrument company, for approximately $392.6 million in cash consideration, plus the assumption of certain liabilities. Following the closing, NanoString’s business operations will no longer...

NanoString Products Drive Breakthrough Cancer Research at the 2024 American Association of Cancer Research (AACR) Conference

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, will present at the 2024 meeting of the American Association of Cancer Research studies delving into metastatic brain tumors, triple-negative breast cancer, pancreatic cancer and dozens of other vital research areas. The conference will be held in San Diego, April 5-10, 2024. NanoString and its customers will showcase 110 posters and highlight its products...

National Geographic Magazine Showcases NanoString’s Spatial Biology Technology to Examine Cell Death in Alzheimer’s Disease

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (OTC: NSTGQ), a leading provider of life science tools for discovery and translational research, today announced that research using the company’s CosMx™ Spatial Molecular Imager (SMI) has been featured for a third time in National Geographic Magazine. A special-interest magazine from National Geographic called Anti-Inflammation, available on newsstands this week, spotlights the role of inflammation on health and disease. The article, “How...
Back to Newsroom
  1. There was an issue with the authorization server. Please contact support if the issue persists.